Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Milan: Philogen suffers in tough session | - | Teleborsa | ||
25.09. | Milan: Major selling for Philogen | - | Teleborsa | ||
23.09. | Milan: Philogen falls | - | Teleborsa | ||
11.06. | Bristol Myers bolsters radiopharma portfolio with PhiloChem deal | 9 | BioPharma Dive | ||
11.06. | Philochem Licenses OncoACP3 Worldwide Rights to RayzeBio | 1 | Contract Pharma | ||
PHILOGEN Aktie jetzt für 0€ handeln | |||||
11.06. | Bristol-Myers' RayzeBio signs a license deal with Philochem | 4 | Seeking Alpha | ||
11.06. | BMS' radiopharma unit builds with $1.35bn Philochem deal | 10 | pharmaphorum | ||
11.06. | Philogen S.p.A.: Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.3 | 880 | GlobeNewswire (Europe) | Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales
OTELFINGEN... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,470 | -1,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
EVOTEC | 6,698 | -0,86 % | Adidas, Bechtle, Bitcoin Group, Evotec, Renk, Ströer - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
BIONTECH | 87,60 | -3,04 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,435 | -7,96 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
VIKING THERAPEUTICS | 29,370 | -2,96 % | Why Shares in Viking Therapeutics Surged This Week | ||
APOGEE THERAPEUTICS | 53,29 | +0,15 % | Apogee Therapeutics sichert sich 323,3 Mio. US-Dollar durch Aktienplatzierung an der NASDAQ | ||
INTELLIA THERAPEUTICS | 20,700 | -6,04 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 10,220 | +8,61 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
JYONG BIOTECH | 56,89 | +6,40 % | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer Prevention | New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company", "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 21,800 | -3,75 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten | ||
TOURMALINE BIO | 47,895 | +0,12 % | Novartis Pharma AG: Novartis announces commencement of tender offer to acquire Tourmaline Bio | Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ("Purchaser"), has commenced a tender offer... ► Artikel lesen | |
CRISPR THERAPEUTICS | 62,00 | -4,62 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
89BIO | 14,825 | -0,17 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
MODERNA | 22,965 | -3,45 % | AstraZeneca ups investment in Virginia; Moderna vets launch VC fund | ||
BEAM THERAPEUTICS | 26,245 | -5,83 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus |